FN-1501

Generic Name
FN-1501
Brand Names
Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
Drug Type
Small Molecule
Chemical Formula
C22H25N9O
CAS Number
1429515-59-2
Unique Ingredient Identifier
6MC966B505
Background

Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...

Indication

Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...

Associated Conditions
Transplanted Organ Rejection
Associated Therapies
-
Clinical Trials
Related News

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

First Posted Date
2005-07-11
Last Posted Date
2017-05-30
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
12
Registration Number
NCT00118352
Locations
🇮🇹

University of Torino, Torino, Italy

🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection

First Posted Date
2005-07-08
Last Posted Date
2015-03-18
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
75
Registration Number
NCT00117689
Locations
🇺🇸

University of Colorado Hospital and Health Sciences Center, Denver, Colorado, United States

🇺🇸

University of Cincinnati Medical Center, Cincinnati, Ohio, United States

🇺🇸

Mount Sinai Medical Center, New York, New York, United States

and more 13 locations

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

First Posted Date
2005-06-08
Last Posted Date
2011-08-11
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
501
Registration Number
NCT00113269

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

First Posted Date
2005-06-03
Last Posted Date
2017-05-24
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
5
Registration Number
NCT00112593
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2005-05-04
Last Posted Date
2011-11-17
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
40
Registration Number
NCT00110058
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

🇺🇸

Seattle Cancer Care Alliance, Seattle, Washington, United States

🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

First Posted Date
2005-03-11
Last Posted Date
2012-12-27
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
27
Registration Number
NCT00105235
Locations
🇺🇸

University of Miami School of Medicine, Miami, Florida, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

and more 6 locations

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

First Posted Date
2005-03-04
Last Posted Date
2019-07-11
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
66
Registration Number
NCT00104858
Locations
🇺🇸

VA Puget Sound Health Care System, Seattle, Washington, United States

🇩🇰

Rigshospitalet University Hospital, Copenhagen, Denmark

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

and more 2 locations

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

First Posted Date
2005-03-04
Last Posted Date
2019-10-30
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
210
Registration Number
NCT00105001
Locations
🇩🇰

Rigshospitalet University Hospital, Copenhagen, Denmark

🇺🇸

Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

🇩🇪

Medizinische Univ Klinik Koln, Koln, Germany

and more 8 locations

Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)

First Posted Date
2005-02-15
Last Posted Date
2024-08-27
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
84
Registration Number
NCT00103792
Locations
🇳🇱

University Medical Centre Groningen, Groningen, Netherlands

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

First Posted Date
2004-11-09
Last Posted Date
2020-01-31
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
36
Registration Number
NCT00096161
Locations
🇺🇸

LDS Hospital, Salt Lake City, Utah, United States

🇺🇸

VA Puget Sound Health Care System, Seattle, Washington, United States

🇮🇹

University of Torino, Torino, Italy

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy